Trastuzumab plus pertuzumab for HER2-mutated cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Mouth & dental, Skin, Women’s health & pregnancy clinical trials.
This trial tests whether combining trastuzumab and pertuzumab can treat cancers that have HER2 amplification or an activating HER2 mutation. It looks at people ages 12 and older, and may include both children/teens and adults, using the study drug based on their HER2 test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 12 or older.
- Your cancer must have HER2 amplification or a specific HER2 activating mutation on a validated genetic test (tumor gene testing).
- You must be able to provide a fresh tissue biopsy and blood samples for study testing.
- You must not have breast cancer that is only early-stage or has already spread (early or metastatic breast cancer).
- Your heart must be healthy enough for this treatment (based on an ejection fraction and recent heart history).
- You must not be allergic to trastuzumab or pertuzumab and must avoid certain live vaccines around treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called trastuzumab rezetecan for people with advanced solid tumors that show a certain protein (HER2). The drug targets HER2 to help kill cancer cells, and the goal is to see if it is safe and effective.
This trial tests a combination of two targeted therapies given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see if this approach is safe and effective for early-stage breast cancer.
This study tests a new combination of two HER2-targeted drugs (trastuzumab and pertuzumab) given after surgery for HER2-positive breast cancer. It looks at whether this combination can help reduce the risk of cancer coming back in people who still had some cancer left after neoadjuvant therapy.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests a new combination of two drugs—trastuzumab, a standard targeted therapy, and retifanlimab, an immunotherapy—for people with early-stage HER2-positive breast cancer. The goal is to see if adding immunotherapy before surgery can improve outcomes.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
Hear when a new Gallbladder Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.